About Zumutor Biologics
Zumutor Biologics is a company based in Bengaluru (India) founded in 2013 by Kavitha Iyer Rodrigues. It operates as a HealthTech. Zumutor Biologics has raised $27.89 million across 8 funding rounds from investors including Accel, Bharat Fund and Aarin Capital. The company has 23 employees as of April 08, 2024. Zumutor Biologics offers products and services including ZM008 and Monoclonal Antibodies. Zumutor Biologics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Bengaluru, India
- Employees 23 as on 08 Apr, 2024
- Founders Kavitha Iyer Rodrigues
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zumutor Biologics Inc
- Date of Incorporation 31 Jul, 2015
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$1.52 M (USD)-40.66as on Mar 31, 2024
-
Net Profit
$161.76 K (USD)-34.59as on Mar 31, 2024
-
EBITDA
$400.26 K (USD)9.72as on Mar 31, 2024
-
Total Equity Funding
$27.89 M (USD)
in 8 rounds
-
Latest Funding Round
$730.41 K (USD), Series A
Nov 27, 2024
-
Investors
Accel
& 9 more
-
Employee Count
23
as on Apr 08, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zumutor Biologics
Zumutor Biologics offers a comprehensive portfolio of products and services, including ZM008 and Monoclonal Antibodies.
ZM008 is developed as an anti-LLT1 antibody therapy.
Monoclonal antibodies are created for targeted therapeutic solutions.
People of Zumutor Biologics
Unlock access to complete
Unlock access to complete
Scientific Team
8 people
Strategic Team
3 people
Leadership Team
2 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of Zumutor Biologics
Zumutor Biologics has successfully raised a total of $27.89M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $730.41 thousand completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zumutor Biologics
Zumutor Biologics has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Accel, Bharat Fund and Aarin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture fund management focusing on deep tech and science investments in India.
|
Locked | Locked | Locked | |
|
Accel is recognized as a leading venture capital firm.
|
Locked | Locked | Locked | |
|
Funding for IP-driven deep-tech and digitization-led inclusive solutions.
|
Locked | Locked | Locked |
Investor details for Zumutor Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zumutor Biologics
Investment portfolio details for Zumutor Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Zumutor Biologics
Detailed financials for Zumutor Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zumutor Biologics Comparisons
Peer comparison for Zumutor Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zumutor Biologics
Zumutor Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of Zumutor Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zumutor Biologics
Complete news archive for Zumutor Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zumutor Biologics
Zumutor Biologics was founded in 2013.
Zumutor Biologics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Kavitha Iyer Rodrigues is the current CEO of Zumutor Biologics. They have also founded this company.
Zumutor Biologics is a funded company, having raised a total of $27.89M across 8 funding rounds to date.
As of Apr 08, 2024, the latest employee count at Zumutor Biologics is 23.
Annual revenue of Zumutor Biologics is $1.52M as on Mar 31, 2024.
Zumutor Biologics is engaged in the discovery and development of novel drug products, particularly in the field of immuno-oncology. The company specializes in targeted NK cell therapeutics using proprietary human antibody platforms like INABLR. Headquartered in Cambridge, MA, USA, with RD facilities in Bangalore, India, Zumutor is involved in creating first-in-class therapeutic antibodies that address innate immunity and tumor microenvironments. Additionally, bespoke services are offered to facilitate partners discovery programs and co-development of monoclonal antibodies.
Zumutor Biologics's top competitors include Moderna, BeiGene and Strand Therapeutics.
Zumutor Biologics offers ZM008 and Monoclonal Antibodies.
Zumutor Biologics has 10 investors. Key investors include Accel, Bharat Fund, Aarin Capital, Karnataka Information Technology Venture Capital Fund, and Siana Capital.